Gelonghui, April 8, 丨 Shijiyao Group (02005.HK) announced that the Group's cephalexin capsules (0.25g and 0.125g) have obtained approval from the China National Drug Administration (“State Drug Administration”) to pass the consistent evaluation of the quality and efficacy of generic drugs. Cephalexin capsules are mainly used to treat acute tonsillitis, angina, sinusitis, bronchitis, pneumonia and other respiratory infections, otitis media, urinary tract infections, and skin and soft tissue infections caused by sensitive bacteria.
Furthermore, the Board of Directors is pleased to announce that the Group's doxazosin mesylate has been approved by the State Drug Administration for registration as an active ingredient for use in marketed formulations. Doxazosin mesylate is an antihypertensive drug, mainly used in patients with primary mild or moderate hypertension and hypertension with benign prostatic hypertrophy.